Finance

Lists
KVUE:NYSE
Kenvue Inc
18,01 US$
+1,41%
(+0,25) 1D
18,00 US$
-0,06% (-0,010)
After hours
Closed: 14 ოქტ, 16:00:05 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KVUE...
Open
17,92 US$
High
18,04 US$
Low
17,76 US$
Mkt. cap
34,59 მლრდ.
Avg. vol.
24,20 მლნ.
Volume
27,61 მლნ.
Dividend
4,66%
Quarterly dividend
0,21 US$
Ex-dividend date
21 სექ. 2026
P/E ratio
20,88
52-wk high
20,13 US$
52-wk low
14,02 US$
EPS
0,86 US$
Beta
0,48
Shares outstanding
1,92 მლრდ.
No. of employees
22 ათ.
Open
17,92 US$
High
18,04 US$
Low
17,76 US$
Mkt. cap
34,59 მლრდ.
Avg. vol.
24,20 მლნ.
Volume
27,61 მლნ.
Dividend
4,66%
Quarterly dividend
0,21 US$
Ex-dividend date
21 სექ. 2026
P/E ratio
20,88
52-wk high
20,13 US$
52-wk low
14,02 US$
EPS
0,86 US$
Beta
0,48
Shares outstanding
1,92 მლრდ.
No. of employees
22 ათ.
News stories
From web sources and news partners
Profile
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey. Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index. CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO. Wikipedia
About Kenvue Inc
CEOKirk Perry
Employees21,9 ათ.
Founded2022
HeadquartersSummit, ნიუ-ჯერსი, ამერიკის შეერთებული შტატები
SectorPersonal care products
Websitekenvue.com
Analyst ratings
Based on 7 analysts giving stock ratings to KVUE in the past 3 months
Hold
Buy
1
Hold
6
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for KVUE in the last 3 months.
Highest
Current 18,01 US$
20,00 US$ (+11,05%)
Average
19,25 US$ (+6,89%)
Lowest
19,00 US$ (+5,50%)
Analyst
Recommendation
Action
Price target
Projected
Date
Filippo Falorni
Citi
Hold
Maintained
19,00 US$
+5,5%
10/14/2026
Susan Anderson
Canaccord Genuity
Buy
Maintained
-
-
09/16/2026
Taylor Conrad
Argus Research
Hold
Maintained
-
-
09/14/2026
Peter Grom
UBS
Hold
Maintained
19,00 US$
+5,5%
08/11/2026
Nik Modi
RBC Capital
Hold
Maintained
20,00 US$
+11%
08/07/2026
Jon Andersen
William Blair
Hold
Maintained
-
-
08/06/2026
Lauren Lieberman
Barclays
Hold
Maintained
19,00 US$
+5,5%
08/06/2026
Javier Escalante
Evercore ISI
Hold
Maintained
18,00 US$
-0,1%
02/18/2026
Keith Devas
Jefferies
Hold
Downgraded
18,00 US$
-0,1%
01/30/2026
Last report
6 აგვ. 2026
Fiscal period
Q2 2026
0,31 US$ / 0,32 US$
-2,82%miss
Revenue / Est. (USD)
3,96 მლრდ. / 3,97 მლრდ.
-0,36%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
3,76 მლრდ.
3,78 მლრდ.
3,91 მლრდ.
3,96 მლრდ.
Cost of goods sold
1,53 მლრდ.
1,63 მლრდ.
1,60 მლრდ.
1,64 მლრდ.
Cost of revenue
1,53 მლრდ.
1,63 მლრდ.
1,60 მლრდ.
1,64 მლრდ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,51 მლრდ.
1,51 მლრდ.
1,45 მლრდ.
1,54 მლრდ.
Operating expense
1,51 მლრდ.
1,48 მლრდ.
1,46 მლრდ.
1,54 მლრდ.
Total operating expenses
3,04 მლრდ.
3,11 მლრდ.
3,06 მლრდ.
3,19 მლრდ.
Operating income
726,00 მლნ.
674,00 მლნ.
845,00 მლნ.
768,00 მლნ.
Other non operating income
10,00 მლნ.
7,00 მლნ.
-
1,00 მლნ.
EBT including unusual items
526,00 მლნ.
427,00 მლნ.
672,00 მლნ.
598,00 მლნ.
EBT excluding unusual items
623,00 მლნ.
574,00 მლნ.
750,00 მლნ.
667,00 მლნ.
Income tax expense
128,00 მლნ.
97,00 მლნ.
198,00 მლნ.
142,00 მლნ.
Effective tax rate
24,33%
22,72%
29,46%
23,75%
Other operating expenses
1,00 მლნ.
-30,00 მლნ.
11,00 მლნ.
6,00 მლნ.
Net income
398,00 მლნ.
330,00 მლნ.
474,00 მლნ.
456,00 მლნ.
Net profit margin
10,57%
8,73%
12,13%
11,53%
Earnings per share
0,28
0,27
0,32
0,31
Interest and investment income
14,00 მლნ.
11,00 მლნ.
11,00 მლნ.
13,00 მლნ.
Interest expense
-107,00 მლნ.
-109,00 მლნ.
-106,00 მლნ.
-103,00 მლნ.
Net interest expenses
-93,00 მლნ.
-98,00 მლნ.
-95,00 მლნ.
-90,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
867,00 მლნ.
713,00 მლნ.
988,00 მლნ.
913,00 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები